重复口服氯胺酮治疗门诊难治性抑郁:随机双盲安慰剂对照概念验证研究
该随机双盲安慰剂对照概念验证试验纳入41例门诊难治性抑郁患者,分别接受1 mg/kg口服氯胺酮或安慰剂每周三次共21天。第21天氯胺酮组MADRS减分12.75分,安慰剂组2.49分(P<0.001);氯胺酮组6例(27.3%)缓解,对照组0例(P<0.05),不良反应轻微短暂。
要点
- 口服氯胺酮1 mg/kg每周三次共21天,第21天MADRS减分显著优于安慰剂。
- 氯胺酮组缓解率27.3%,对照组0%,需治疗人数为3.7。
- 不良反应轻微且短暂,支持门诊社区场景下辅助口服氯胺酮的可行性。
核心结论
- 重复口服氯胺酮对门诊难治性抑郁患者产生快速且持续的抑郁症状改善,且耐受性良好。
- 结果提示辅助口服氯胺酮在社区难治性抑郁患者照护中可能具有重要前景。
研究设计与样本
- 随机、双盲、安慰剂对照概念验证试验,共41例门诊难治性抑郁患者。
- 参与者接受1 mg/kg口服氯胺酮或安慰剂,每周三次,共21天(ClinicalTrials.gov标识NCT02037503)。
- 评估时间点为基线、给药后40和240分钟以及第3、7、14和21天,主要结局为MADRS评分变化。
主要发现
- 氯胺酮组在所有时间点均可见抑郁症状减轻,对照组仅在给药后40分钟可见减轻。
- 第21天MADRS减分氯胺酮组为12.75分,安慰剂组为2.49分(P<0.001)。
- 氯胺酮组6例(27.3%)达到缓解,对照组0例(P<0.05),缓解的需治疗人数为3.7。
- 不良反应轻微且短暂。
关键数值与推荐
- 口服氯胺酮剂量为1 mg/kg,每周三次,持续21天。
- 主要结局指标为蒙哥马利-奥斯伯格抑郁评定量表(MADRS)评分变化。
- 第21天MADRS减分:氯胺酮组12.75分 vs 安慰剂组2.49分(P<0.001)。
- 缓解率:氯胺酮组27.3% vs 对照组0%(P<0.05),缓解需治疗人数3.7。
临床怎么用
- 对于门诊难治性抑郁患者,可考虑在现有治疗基础上辅助使用口服氯胺酮1 mg/kg每周三次共21天。
- 治疗期间需在给药后40分钟和240分钟以及第3、7、14和21天评估MADRS评分以监测疗效。
- 口服氯胺酮不良反应轻微短暂,但仍需在门诊环境中进行安全监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ketamine has been demonstrated to improve depressive symptoms.AimsEvaluation of efficacy, safety and feasibility of repeated oral ketamine for out-patients with treatment-resistant depression (TRD). METHOD: In a randomised, double-blind, placebo-controlled, proof-of-concept trial, 41 participants received either 1 mg/kg oral ketamine or placebo thrice weekly for 21 days (ClinicalTrials.gov Identifier: NCT02037503). Evaluation was performed at baseline, 40 and 240 min post administration and on days 3, 7, 14 and 21. The main outcome measure was change in Montgomery-Åsberg Depression Rating Scale (MADRS). RESULTS: Twenty-two participants were randomised to the ketamine group, and 19 to the control, with 82.5% (n = 33) completing the study. In the ketamine group, a decrease in depressive symptoms was evident at all time points, whereas in the control group a decrease was evident only 40 min post administration. The reduction in MADRS score on day 21 was 12.75 in the ketamine group versus 2.49 points with placebo (P < 0.001). Six participants in the ketamine group (27.3%) achieved remission compared with none of the controls (P < 0.05). The number needed to treat for remission was 3.7. Side-effects were mild and transient. CONCLUSIONS: Repeated oral ketamine produced rapid and persistent amelioration of depressive symptoms in out-patients with TRD, and was well tolerated. These results suggest that add-on oral ketamine may hold significant promise in the care of patients suffering from TRD in the community.Declaration of interestNone.
引用
- Domany Y, Bleich-Cohen M, Tarrasch R, et al. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study. Br J Psychiatry. 2018. PMID: 30246667. doi:10.1192/bjp.2018.196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。